ACTU Stock Analysis: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$0.96
-0.01 (-1.52%)
▼
5d:
-22.35%
30d:
-44.47%
90d:
-67.84%
WAIT
LOW Confidence
Analysis Updated: Aug 12, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACTU is down 22.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACTU is down 22.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $0.96, which is considered oversold relative to its 30-day fair value range of $1.04 to $1.47.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $0.91, while resistance sits at $1.25.
Market Sentiment: ACTU scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.98 (+928.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $0.91, while resistance sits at $1.25.
Market Sentiment: ACTU scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.98 (+928.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.04 -
$1.47
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 928.7% below Wall St target ($9.98)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.04 -
$1.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.91
Resistance Level
$1.25
Current Trend
Strong Downtrend
Technical data as of
Aug 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.14
Wall Street Target
$9.98
(+928.7%)
Share & Embed Analysis
Last updated: August 13, 2026 12:36 PM ET
Data refreshes hourly during market hours. Next update: 1:36 PM
Data refreshes hourly during market hours. Next update: 1:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 41 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 59 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$59 | 52 HOLD |
